Thursday 16 October, 2025
Objectives: Physiological changes during pregnancy are well known and these have various effects on drug pharmacokinetics (PK). The objective of…
Read morePoster: Methodology - Covariate/Variability Models
Adjusted adaptive lasso for covariate model building in nonlinear mixed effects models
Thursday 16 October, 2025
Objectives: This study aimed to propose and implement a new version of lasso, Adjusted Adaptive Lasso [1], for non-linear mixed…
Read moreApplying parametric bootstrap to generating a distribution of pseudo-objective function value difference for model selection in population pharmacokinetic analysis under time zone-specific nonexistence of observations
Thursday 16 October, 2025
Introduction: The likelihood ratio test is typically conducted to evaluate whether a candidate covariate should be included into or excluded…
Read moreHierarchical Bayesian-PBPK modeling for physiological characterization and extrapolation of patient populations from clinical data
Thursday 16 October, 2025
Objectives: The identification of interindividual variability from clinical pharmacokinetic data using a hierarchical Bayesian approach in combination with large-scale physiologically-based…
Read moreHandling inter-occasion variability in model implementation for Bayesian forecasting: A comparison of methods and metrics.
Thursday 16 October, 2025
Objectives: Inter-occasion variability (IOV) can substantially impact the accuracy and precision in Bayesian forecasting (BF) in the context of therapeutic…
Read moreInvestigating the Importance of Considering Inter-correlations of Cytochrome P450 Enzyme Abundances in Human Liver When Predicting Drug-Drug Interactions
Thursday 16 October, 2025
Objectives: We have previously compared the marginal distribution of 13 hepatic CYP450 enzymes with and without considering inter-correlations of absolute abundances…
Read moreTowards more Realistic Clinical Trial Simulation: Establishing Inter-Correlations between Several Cytochrome P450 Enzyme Abundances in Human Liver
Thursday 16 October, 2025
Objectives: Success of clinical trial simulations greatly depends on identifying and incorporating true anatomical and physiological covariates when generating virtual populations….
Read moreExploring fixed dose versus body weight based dosing for monoclonal antibodies using physiologically based pharmacokinetic modelling.
Thursday 16 October, 2025
Objectives: To determine whether physiologically based pharmacokinetic (PBPK) models, which incorporate covariates and interindividual variability in systems parameters, are effective…
Read moreEmerging covariates on the pharmacokinetics of monoclonal antibodies: Do current PBPK models account for the covariates identified in POPPK studies?
Thursday 16 October, 2025
Objectives: To identify covariates that impact significantly on the pharmacokinetic (PK) parameters of monoclonal antibodies (mAbs) in population pharmacokinetic (POPPK) studies…
Read moreCovariate model selection in an Alzheimer disease progression model
Thursday 16 October, 2025
Objectives: Although in the past two decades hundreds of molecules were tested against Alzheimer disease (AD) only five for symptomatic…
Read more